Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May;20(4):111-113.
doi: 10.1080/15265161.2020.1730490.

Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?

Liza-Marie Johnson  1 , Devan M Duenas  2 , Benjamin S Wilfond  2   3
Affiliations
Case Reports

Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?

Liza-Marie Johnson et al. Am J Bioeth. 2020 May.
No abstract available

PubMed Disclaimer

References

    1. Ardoin SP, and Schanberg LE. 2012. Lessons from SLE: Children are not little adults. Nature Reviews Rheumatology 8 (8): 444–445. doi: 10.1038/nrrheum.2012.109. - DOI - PubMed
    1. Food and Drug Administration (FDA). 2019a. 21 CFR Part 50.52 Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects. Revised 1 April 2019 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?C... (accessed December 24, 2019)
    1. Food and Drug Administration (FDA). 2019b. 21 CFR Part Clinical investigations involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subjects’ disorder or condition. Revised 1 April 2019 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?C... (accessed December 24, 2019)
    1. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. 2016. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nature Medicine 22(9): 991–993. doi: 10.1038/nm.4148. - DOI - PubMed
    1. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Katz P, Criswell LA, and Yelin E. 2009. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Care and Research 61(1): 13–20. doi: 10.1002/art.24091. - DOI - PMC - PubMed

Publication types